SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing a sharp surge in investor interest and bullish momentum following optimistic CEO commentary regarding the survival data of its REGAL Phase 3 clinical trial. The community is actively discussing the potential for an imminent short squeeze and institutional accumulation as they wait for the final 80th trial event, with many retail investors highlighting the immunotherapy platform as a major, de-risked candidate for significant valuation growth.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amid intense community polarization, with critics highlighting government settlement news and concerns over financial transparency, while supporters focus on political alignments and upcoming election developments. Investors are actively debating the company's valuation and long-term viability, characterized by high volatility and significant skepticism regarding its ongoing financial performance.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the FDA's acceptance of their supplemental BLA for ANKTIVA in bladder cancer, with a PDUFA date set for January 6, 2027. Investors are actively discussing this regulatory milestone as a major catalyst that could significantly expand the addressable market for the companys flagship therapy, despite some community frustration over the timeline and ongoing volatility from short sellers.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

Investors are actively debating the long-term growth prospects of e.l.f. Beauty ahead of its upcoming earnings report, weighing the "lipstick effect" and strong brand momentum against concerns over high inflation, tariff impacts, and recent downward price pressure. While some community members view the current volatility as a manipulation-driven "shakeout" that offers a buying opportunity for a resilient consumer staples leader, others remain cautious about potential downward revisions to guidance.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

VanEck Gold Miners ETF (GDX) is trending as it approaches a key support zone between $77 and $82, a level technical analysts are monitoring for a potential reversal in the current corrective decline. The community remains divided, with some traders actively looking for a bullish rebound from these support levels while others are highlighting the increased operational pressure on miners due to rising energy costs.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending following news that China has agreed to a 200-aircraft order, a development met with volatile trading as some investors expressed disappointment compared to higher speculative expectations. The community is actively debating whether this deal signals a long-term turnaround for the company's backlog and production execution or if it serves as a 'sell-the-news' event for a stock that has faced significant recent headwinds.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is surging following a strong quarterly earnings report that featured an earnings beat, raised full-year guidance, and impressive same-store sales growth. The community is actively debating the company's high valuation against its rapid expansion and 'no-discount' strategy, with bulls highlighting its debt-free balance sheet while bears remain skeptical of the stock's premium price-to-earnings multiple.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently the primary focus for market participants as investors brace for high-stakes earnings that could define the near-term trajectory for AI-linked stocks and broader market sentiment. The community is heavily split, with intense debate over whether the stock will break out or trigger a sell-the-news reaction, while many are closely watching for updates on Blackwell shipments and forward guidance to validate the ongoing AI infrastructure spending thesis.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is trending as investors debate the impact of a recent short-seller report against the company's strong fundamentals, including growing ASCENIV demand, margin expansion, and an active share repurchase program. The community is actively discussing the stock's discounted valuation following the volatility, with many focusing on upcoming earnings as a potential catalyst for a price recovery.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp is attracting intense community attention as traders analyze its production milestones at the Burke Hollow project and strong balance sheet, while positioning for a potential squeeze ahead of growth initiatives. Market participants are actively debating the stock's support levels and its strategic role as a domestic supplier, with many retail investors viewing current volatility as an opportunity to build long-term positions amid the broader nuclear energy renaissance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Defense, Biotech, and Aerospace Stories Dominate

Markets are opening Thursday with a mix of defense innovation, biotech progress, aerospace supply chain momentum, and turnaround earnings, highlighting how technology and strategic manufacturing continue to drive investor attention across several sectors. From next-generation biomaterials to counter-drone systems and aerospace electronics, the latest corporate developments suggest continued capital flow toward industries tied to national security, healthcare innovation, and advanced manufacturing. $KBLB, $IBO, $GXAI, $MOBX, $BTAI, $ALTO

<ul class="summary-bullets"><li>Under the revised agreement, the combined public company will issue around 169.6 million ordinary shares.</li><li>The combined public company will also issue 128,000 shares to DSS, its parent company.</li><li>This follows a June 2025 agreement to combine Dr Ashleys’ manufacturing with Impact BioMedical’s portfolio of more than 90 medical patents.</li></ul>Shares of Impact BioMedical (IBO) soared over 65% in pre-market trading on Thursday, after the company announced amendments to agreements tied to its planned merger with Dr Ashleys.If the pre-market level holds after the opening bell, <a href="https://stocktwits.com/symbol/IBO">IBO stock</a> would hit its highest since Sept. 12, 2025.<h2 class="st-heading-2">PubCo To Issue 169.6 Million Shares</h2>Under the revised agreement, the combined public company, referred to as PubCo, will issue 169,560,000 ordinary shares, which represent about 94.2% of PubCo’s outstanding shares at the closing of the business combination. These shares are called the Company Share Consideration.PubCo will issue 22,000 shares to Impact’s CEO, Frank D. Heuszel, and up to 128,000 shares to DSS in two batches. DSS is the parent company of Impact BioMedical. These shares will be&nbsp;deducted from the PubCo’s Company Share Consideration.Additionally, the deadline to complete the merger was extended from March 31, 2026, to July 1, 2026, while shareholders who support the transaction currently control about 88.9% of Impact BioMedical’s shares.<h2 class="st-heading-2">Merger To Open Up Manufacturing Access For Impact</h2>In June 2025, Impact BioMedical and Dr Ashleys signed a definitive merger agreement with Dr Ashleys. The transaction will create a new holding company that will own both Dr Ashleys and Impact BioMedical as subsidiaries. The combined company will be led by Dr Ashleys’ executive team and a newly appointed board.The merger aims to combine Dr Ashleys’ manufacturing and global market access with Impact BioMedical’s portfolio of more than 90 patents covering treatments for cancer, infectious diseases, respiratory illnesses, and orphan drugs.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>The stock garnered significant retail buzz, with Stocktwits data indicating a 14,200% increase in message volumes over the past 24 hours, while retail sentiment on the platform turned ‘extremely bullish’ from ‘bullish’ a day back.<img src="https://news.stocktwits-cdn.com/ibo_jpg_729ebe600c.webp" alt="ibo.jpg">One user sees a rally if the stock breaks over $0.8. It is currently at $0.69.<stembedurl>https://stocktwits.com/TroubleMaker/message/646636004</stembedurl>Another user sees the stock climbing to the $2.45 - $3 range.<stembedurl>https://stocktwits.com/Flybeast/message/646657749</stembedurl>Year-to-date, the stock has gained around 36%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-btai-stock-surge-in-pre-market-today/cZdQs29RI3E">Why Did BTAI Stock Surge 20% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IBO Stock Surge 65% In Pre-Market Today?

The company announced amendments to agreements related to its planned merger with Dr. Ashley's, including extending the deadline to complete the merger to July 1, 2026.

IBO Stock Spikes Pre-Market: Retail Traders Pile Into Biotech Penny Stock After Merger Update

Equity

Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The firm focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological and immune related diseases. It is also involved in developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The company was founded on October 16, 2018 and is headquartered in Houston, TX.

IBO
Impact BioMedical Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest IBO News

IBOImpact BioMedical Inc.